LKFT | Ticker Profile - Titan Protect

LKFT

Lakefront Biotherapeutics NV

Healthcare · Biotechnology · NMS

$28.02

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.8B

Total market value of the company

Trailing P/E

3.22

Very cheap relative to earnings

Forward P/E

-9.22

Based on estimated future earnings — lower means cheaper

Rev Growth

-91.4%

Year-over-year revenue change

Profit Margin

46.8%

How much profit the company keeps from each dollar of revenue

ROE

16.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$23.33

-17% from current price — median analyst estimate

Recommendation

HOLD

Consensus view from 2 analysts covering this stock

About Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

https://lakefrontbio.com

Country: Belgium Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.238

Positive but modest risk-adjusted returns

Kelly Fraction

0.0007

Marginal edge — very small allocation suggested

Calmar Ratio

0.087

Drawdown risk outweighs the returns — higher risk profile

Annual Return

2.5%

Historical annualised return based on price data

Max Drawdown

-29.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.12

Very low correlation to market moves

52W High

$37.78

26% below the year high

52W Low

$26.42

6% above the year low

Avg Volume

167,162

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

4.0%

Low short interest — limited bearish positioning

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$8.62

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.20

Conservative use of debt — low financial risk

Current Ratio

30.48

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

30.24

Like current ratio but excludes inventory — stricter test

Gross Margin

68.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-982.9%

Profit from core operations before interest and tax

Free Cash Flow

$211M

Positive — the business generates more cash than it spends

Revenue (TTM)

$1.0B

Total revenue over the last 12 months

Net Income

$488M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$27.67

Target Median

$23.33

Target Low

$18.99

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go